153 related articles for article (PubMed ID: 37035636)
1. Tissue-resident memory T cells in immune-related adverse events: friend or foe?
Reschke R; Gajewski TF
Oncoimmunology; 2023; 12(1):2197358. PubMed ID: 37035636
[TBL] [Abstract][Full Text] [Related]
2. Tissue-resident memory T cells in immunotherapy and immune-related adverse events by immune checkpoint inhibitor.
Xiong H; Shen Z
Int J Cancer; 2024 Jul; 155(2):193-202. PubMed ID: 38554117
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines.
Reschke R; Shapiro JW; Yu J; Rouhani SJ; Olson DJ; Zha Y; Gajewski TF
Cancer Immunol Res; 2022 Oct; 10(10):1167-1174. PubMed ID: 35977003
[TBL] [Abstract][Full Text] [Related]
4. The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma-two sides of the same coin?
Reschke R; Deitert B; Enk AH; Hassel JC
Front Immunol; 2024; 15():1385781. PubMed ID: 38562921
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations.
Williams KC; Gault A; Anderson AE; Stewart CJ; Lamb CA; Speight RA; Rajan N; Plummer R; Pratt AG
Front Immunol; 2023; 14():1122430. PubMed ID: 36776862
[TBL] [Abstract][Full Text] [Related]
6. Elevated circulating memory T cells precede immunotherapy toxicities in melanoma.
Bello E; Dougan M
Trends Cancer; 2022 May; 8(5):347-349. PubMed ID: 35277376
[TBL] [Abstract][Full Text] [Related]
7. Resident memory T cells, critical components in tumor immunology.
Mami-Chouaib F; Blanc C; Corgnac S; Hans S; Malenica I; Granier C; Tihy I; Tartour E
J Immunother Cancer; 2018 Sep; 6(1):87. PubMed ID: 30180905
[TBL] [Abstract][Full Text] [Related]
8. Tissue-resident memory CD8
Wang T; Shen Y; Luyten S; Yang Y; Jiang X
Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
[TBL] [Abstract][Full Text] [Related]
9. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
10. Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time?
Abdeljaoued S; Arfa S; Kroemer M; Ben Khelil M; Vienot A; Heyd B; Loyon R; Doussot A; Borg C
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35470231
[TBL] [Abstract][Full Text] [Related]
11. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Luoma AM; Suo S; Williams HL; Sharova T; Sullivan K; Manos M; Bowling P; Hodi FS; Rahma O; Sullivan RJ; Boland GM; Nowak JA; Dougan SK; Dougan M; Yuan GC; Wucherpfennig KW
Cell; 2020 Aug; 182(3):655-671.e22. PubMed ID: 32603654
[TBL] [Abstract][Full Text] [Related]
12. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
14. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.
Beumer-Chuwonpad A; Taggenbrock RLRE; Ngo TA; van Gisbergen KPJM
Cells; 2021 Aug; 10(9):. PubMed ID: 34571883
[TBL] [Abstract][Full Text] [Related]
15. Interferon-Gamma-Producing CD8
Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
[TBL] [Abstract][Full Text] [Related]
16. [Advances in the Study of Tissue-resident Memory T Cells in Lung Cancer].
Tan S; Tian P
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):862-869. PubMed ID: 36617472
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint blockade toxicities: Insights into autoimmunity and treatment.
Walsh MJ; Dougan M
Semin Immunol; 2021 Feb; 52():101473. PubMed ID: 33726931
[TBL] [Abstract][Full Text] [Related]
18. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.
Hsiehchen D; Watters MK; Lu R; Xie Y; Gerber DE
JAMA Netw Open; 2019 Sep; 2(9):e1911519. PubMed ID: 31532516
[TBL] [Abstract][Full Text] [Related]
19. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
Dhodapkar MV; Dhodapkar KM
Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
[TBL] [Abstract][Full Text] [Related]
20. Tissue-resident memory T cells in gastrointestinal tumors: turning immune desert into immune oasis.
Liang M; Wang X; Cai D; Guan W; Shen X
Front Immunol; 2023; 14():1119383. PubMed ID: 36969190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
